The Baseline Features and CHA2DS2 VASc /HAS BLED Scores of Jordanian Patients With Atrial Fibrillation and the One Year Outcome
Sponsor study identifier
observational
2,020
1 country
8
Study Start
May 25, 2019
Actual (reported)Primary Completion
November 25, 2021
Actual (reported)Study Completion
November 25, 2021
Actual (reported)The Jordanian AF study, the first of its kind in Jordan, will evaluate patients with AF in an in-patient and out-patient settings. The morbidity and mortality associated with AF has not been studied in this region especially with the relation to the HAD BLED and CHADS VAC score.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 25, 2021
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 14, 2019
Actual (reported)April 17, 2019
Actual (reported)May 25, 2019
Actual (reported)November 25, 2021
Actual (reported)November 25, 2021
Actual (reported)Stroke and systemic embolization at one year
Stroke that develops from enrollment to one year of follow up (Scale: 0= no stroke at one year, 1= stroke at one year). Systemic embolization that develops in any arterial bed other than the brain from enrollment to one year of follow up (Scale: no systemic embolization at one year =0, systemic embolization at one year=1)
one year
Major bleeding events at one year
Major bleeding events from enrollment to one year of follow up including: intracranial bleeding (scale: present= 1, absent=0), hospitalization for bleeding (scale: present=1, absent=2), hemoglobin decrease more than 2 gm/dL (scale: 1=present, 2=absent), and /or transfusion (scale: 1=present, 0=absent).
one year
All consecutive admissions aged 18+ years with new onset or known AF Admitted to participating hospitals
Istishari Hospital
Amman, 11184, Jordan
The University of Jordan
Amman, 11942, Jordan
Ep Clinics Khalidi S
Amman, Jordan
Integrated Center for Cardiovascular and Electric Diseases
Amman, Jordan
Jordan Hospital
Amman, Jordan
Khalidi Hospital & Medical Center
Amman, Jordan
Specialty Hospital
Amman, Jordan
Al-Kasasbeh A, Alghzawi AA, Alfakhouri A, Kadri N, Aloqaily A, Al-Oakily M, Awad B, Hammoudeh AJ. Clinical Profiles of Hospitalized Middle Eastern Patients With Nonvalvular Atrial Fibrillation: Analysis From the JoFib Study. Int J Vasc Med. 2026 Aug 7;2026:6426995. doi: 10.1155/ijvm/6426995. eCollection 2026.
Abdin B, Abuqweider E, Alhaddad I, Shabaneh R, Bader G, Bader T, Abu-Shaban M, Salah Q, Hammoudeh A. The Effect of Multimorbidity and Anticoagulation Use in Patients with Atrial Fibrillation on The One-Year Outcome: Analysis from Jordan Atrial Fibrillation (JoFIB) Study - A Prospective Cohort Study. BMJ Open. 2025 Dec 28;15(12):e102661. doi: 10.1136/bmjopen-2025-102661.
Ayman Hammoudeh, MD, FACC
Cardiology Dept, Istishari Hospital, Amman, Jordan
2,020 participants (actual enrollment reported by the registry).
First Submitted
April 14, 2019
First Posted
April 17, 2019
Study Start
May 25, 2019
Actual (reported)Screening for Atrial Fibrillation in Native AmeRicans Using iPhone ECG
Contact the study team to confirm eligibility.
King Abdullah University Hospital
Irbid, Jordan
Hammoudeh A, Badaineh Y, Tabbalat R, Ahmad A, Bahhour M, Ja'ara D, Shehadeh J, Jum'ah MA, Migdad A, Hani M, Alhaddad IA. The Intersection of Atrial Fibrillation and Coronary Artery Disease in Middle Eastern Patients. Analysis from the Jordan Atrial Fibrillation Study. Glob Heart. 2024 Mar 12;19(1):29. doi: 10.5334/gh.1312. eCollection 2024.
Alrabadi N, Al-Nusair M, Haddad R, Alburie L, Mhaidat N, Aljarrah M, Hamoudeh A. Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study. Eur J Clin Pharmacol. 2024 Apr;80(4):545-552. doi: 10.1007/s00228-024-03622-8. Epub 2024 Jan 23.
Al-Makhamreh H, Alrabadi N, Haikal L, Krishan M, Al-Badaineh N, Odeh O, Barqawi T, Nawaiseh M, Shaban A, Abdin B, Khamies L, Hammoudeh A. Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study. Int J Environ Res Public Health. 2022 May 19;19(10):6173. doi: 10.3390/ijerph19106173.
Alhaddad Z, Hammoudeh A, Khader Y, Alhaddad IA. Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Vasc Health Risk Manag. 2022 Apr 15;18:289-295. doi: 10.2147/VHRM.S360822. eCollection 2022.
Hammoudeh AJ, Khader Y, Kadri N, Al-Mousa E, Badaineh Y, Habahbeh L, Tabbalat R, Janabi H, Alhaddad IA. Adherence to the 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline on the Use of Oral Anticoagulant Agents in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study. Int J Vasc Med. 2021 Apr 8;2021:5515089. doi: 10.1155/2021/5515089. eCollection 2021.
Primary Completion
November 25, 2021
Actual (reported)Study Completion
November 25, 2021
Actual (reported)Last Updated
May 25, 2023
Record last verified: 2023-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: